Emerging Health Care Innovation Brief: Treating Post-COVID Conditions and Preventing Fetal and Neonatal Alloimmune Thrombocytopenia (August 17-30, 2023)
Download this Innovation Brief
Highlights
Highlights provide a timely synopsis of selected interesting developments emerging in the past 2 weeks from the information universe covered by the PCORI Health Care Horizon Scanning System (HCHSS). Information covers currently emerging innovations in patient-centered care that may or may not be directly related to the Topics to Watch. The views presented here are solely those of ECRI Horizon Scanning and have not been vetted by other stakeholders.
With summer ending, the Centers for Disease Control and Prevention reports that new COVID-19 hospitalizations are rising, from 6461 on July 8, 2023, to 15 067 on August 19, 2023. As acute infections increase, so could the importance of investigational therapies such as IMC-2 (valacyclovir plus celecoxib), now under study for post-COVID conditions (PCC, also known as long COVID, see Topics to Watch). Such developer-led research into new PCC treatments might give providers much-needed insight. As the media have reported the National Institutes of Health’s RECOVER research initiative is focused on observational trials to learn about the long-term effects of COVID, and funding is limited for prospective randomized treatment trials that would be expected to elucidate effective treatments. Concerns were raised as early as April 2023.
Developing protections against other respiratory viruses will also be important as cold and flu season arrives. On August 21, 2023, the US Food and Drug Administration (FDA) approved Abrysvo as the first maternal vaccine targeting respiratory syncytial virus (RSV) and intended to prevent severe respiratory infections in infants from birth through 6 months.
In earlier-stage research on maternal-fetal health, developers are testing whether an investigational antibody can prevent a pregnant woman’s immune system from destroying fetal blood platelets and causing severe fetal bleeding (see Topics to Watch).
Another regulatory first occurred August 18, 2023, when the FDA made pozelimab-bbfg (Veopoz) the first approved therapy for treating CHAPLE disease (CD55-deficient protein-losing enteropathy), an ultrarare, potentially fatal autoimmune disease affecting children and adults.
Topics to Watch
ECRI Horizon Scanning has selected the topics below as those with potential for impact within the PCORI HCHSS’s focus areas in the United States within the next 3 years. All views presented are preliminary and based on readily available information at the time of writing. Because these topics are rapidly developing, we cannot guarantee the accuracy of this information after the date listed on this publication. In addition, all views expressed in the commentary section are solely those of ECRI Horizon Scanning and have not been vetted by other stakeholders. Topics are listed in alphabetical order.
IMC-2 (Valacyclovir plus Celecoxib) to Treat Post-COVID Conditions
At a Glance
|
For a description and commentary about this topic/issue, download this Innovation Brief.
RLYB212 to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
At a Glance
|
For a description and commentary about this topic/issue, download this Innovation Brief.
Horizon scanning is a systematic process that serves as an early alert system to inform decision makers about possible future opportunities and threats. Health care horizon scanning identifies technologies, innovations, and trends with the potential to cause future shifts or disruptions—positive or negative—in areas such as access to care, care delivery processes, care setting, costs of care, current treatment models or paradigms, health disparities, health care infrastructure, public health, and patient health outcomes.
The PCORI Health Care Horizon Scanning System (HCHSS) conducts horizon scanning to better inform research investments at the Patient-Centered Outcomes Research Institute (PCORI). PCORI defines the HCHSS project scope to focus on interventions with high potential for disruption in the United States in the next 12 months within 6 focus areas: Alzheimer’s disease and other dementias, cancer, cardiovascular diseases, infectious diseases (including COVID-19), mental and behavioral health conditions, and rare diseases. In addition, the system captures high-level disruptive trends across all clinical areas, which may lead PCORI to expand the project scope to include other focus areas in the future.
The HCHSS produces 3 main outputs:
- Emerging Health Care Innovation Brief provides ECRI Horizon Scanning with a vehicle to inform PCORI and the public in a timely manner of important topics of interest identified during ongoing scanning and topic identification or through the ECRI stakeholder survey process.
- PCORI’s Horizon Scanning Database offers health care decision makers findings about advancements in the HCHSS’s 6 focus areas. This database can be used by patients, care partners, and others to track advancements in care options.
- High Potential Disruption Reports (every 6 months) for individuals with vested interests in new technologies, services, and innovations. It might provide critical insights and information about the areas in which they have a vested interest, which might include their vision and plans for how they intend to adopt an innovation. These reports highlight those topics that stakeholders (eg, patients, physicians, nurses, allied health professionals, public health professionals, first responders, health systems experts, clinical engineers, researchers, business and finance professionals, and information technology professionals) identified as having potential for high disruption.
In January 2023, the HCHSS Biweekly COVID-19 Scans were broadened in scope to include any emerging intervention in the HCHSS and renamed as the Emerging Health Care Innovation Brief.
Back to Main Page Download this Innovation Brief
We welcome your comments on this Innovation Brief at [email protected].
Posted: September 14, 2023
What's Happening at PCORI?
The Patient-Centered Outcomes Research Institute sends weekly emails about opportunities to apply for funding, newly funded research studies and engagement projects, results of our funded research, webinars, and other new information posted on our site.
Image
